Erasca Announces Poster Presentation at the 2023 AACR Annual Meeting
Erasca Inc. (Nasdaq: ERAS) announced a poster presentation at the AACR Annual Meeting on April 18, 2023, discussing preliminary Phase 1 dose escalation data for ERAS-601, a potential best-in-class SHP2 inhibitor, in combination with cetuximab. This study focuses on advanced or metastatic solid tumors. The poster will be available online post-presentation. The company emphasized its mission to develop therapies targeting RAS/MAPK pathway-driven cancers and highlighted the scientific expertise behind its cancer treatments. Caution is advised regarding forward-looking statements on product efficacy and potential risks in clinical development.
- Presentation of promising preliminary dose escalation data for ERAS-601.
- Targeting a significant indication in advanced or metastatic solid tumors.
- Potential to establish ERAS-601 as a best-in-class therapy in its category.
- Forward-looking statements highlight risks regarding product efficacy and clinical development uncertainties.
- Dependence on third parties for manufacturing and clinical testing could impede progress.
Poster will feature preliminary Phase 1 dose escalation data for potential best-in-class SHP2 inhibitor ERAS-601 in combination with cetuximab
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the company will present a poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-19, 2023, in Orlando, Florida.
The abstract will be available on the AACR meeting website. The poster will be available online at Erasca.com/science/presentations following the presentation.
Poster Presentation Details
- Abstract CT184 – Preliminary dose escalation results of ERAS-601 in combination with cetuximab in FLAGSHP-1: A Phase 1 study of ERAS-601, a potent and selective SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors
Date/Time: Tuesday, April 18, 2023, 9:00 AM - 12:30 PM ET
Session: First-in-Human Phase I Clinical Trials 2
Presenter: Dr. Meredith McKean, Sarah Cannon Research Institute at Tennessee Oncology
Location: Orange County Convention Center, Poster Section 45, Poster Board 16
About Erasca
At Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.
Cautionary Note Regarding Forward-Looking Statements
Erasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: our expectations regarding the potential therapeutic benefits of our product candidates, including ERAS-601. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: our approach to the discovery and development of product candidates based on our singular focus on shutting down the RAS/MAPK pathway, a novel and unproven approach; potential delays in the commencement, enrollment, and completion of clinical trials and preclinical studies; our dependence on third parties in connection with manufacturing, research, and preclinical and clinical testing; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval, and/or commercialization, or may result in recalls or product liability claims; unfavorable results from preclinical studies or clinical trials; results from preclinical studies or early clinical trials not necessarily being predictive of future results; the inability to realize any benefits from our current licenses, collaborations, and acquisitions and any future licenses, collaborations, or acquisitions, and our ability to fulfill our obligations under such arrangements; regulatory developments in the United States and foreign countries; our ability to obtain and maintain intellectual property protection for our product candidates and maintain our rights under intellectual property licenses; our ability to fund our operating plans with our current cash, cash equivalents, and marketable securities; our ability to maintain undisrupted business operations due to the COVID-19 pandemic and global geopolitical events, such as the ongoing conflict between Russia and Ukraine; unstable market and economic conditions having serious adverse consequences on our business, financial condition and stock price; and other risks described in our prior filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K for the year ending December 31, 2021, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
FAQ
What is the significance of the ERAS-601 presentation at the AACR Annual Meeting?
When is the ERAS-601 poster presentation scheduled?
What type of cancer is ERAS-601 targeting?
What are the potential risks mentioned in the Erasca press release?
What information will be available after the poster presentation?
